R

Respiri Ltd
ASX:RSH

Watchlist Manager
Respiri Ltd
ASX:RSH
Watchlist
Price: 0.082 AUD 1.23% Market Closed
Market Cap: 105.9m AUD
Have any thoughts about
Respiri Ltd?
Write Note
RSH
/
Cash Flow Statement
/
Capital Expenditures

Respiri Ltd
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Respiri Ltd
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
R
Respiri Ltd
ASX:RSH
Capital Expenditures
AU$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ImpediMed Ltd
ASX:IPD
Capital Expenditures
-AU$3.1m
CAGR 3-Years
-8%
CAGR 5-Years
-7%
CAGR 10-Years
-59%
C
Cyclopharm Ltd
ASX:CYC
Capital Expenditures
-AU$905.5k
CAGR 3-Years
-21%
CAGR 5-Years
0%
CAGR 10-Years
-2%
Cochlear Ltd
ASX:COH
Capital Expenditures
-AU$89.8m
CAGR 3-Years
-10%
CAGR 5-Years
5%
CAGR 10-Years
-11%
Optiscan Imaging Ltd
ASX:OIL
Capital Expenditures
-AU$87.4k
CAGR 3-Years
-41%
CAGR 5-Years
-81%
CAGR 10-Years
N/A
EMvision Medical Devices Ltd
ASX:EMV
Capital Expenditures
-AU$302.4k
CAGR 3-Years
-33%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Respiri Ltd
Glance View

Market Cap
105.9m AUD
Industry
Health Care

Respiri Ltd. engages in research, development, and commercialization of medical devices and the production of mobile health applications for management of asthma and related chronic respiratory diseases. The company is headquartered in Melbourne, Victoria. The company went IPO on 2000-07-14. The firm's segments include Australia and Israel. The Australia segment is engaged in research, development and commercialization of medical devices, and the production of mobile health applications in Australia. The Israel segment is engaged in research, development and commercialization of medical devices, and the production of mobile health applications in Israel. The firm has developed a wheezo, which is an eHealth Saas platform that uses a device and app to measure, record and assist asthma monitoring. Its device and app make up a cloud-based mobile health platform that records wheeze and other clinically relevant symptoms and signs of asthma.

RSH Intrinsic Value
0.008 AUD
Overvaluation 91%
Intrinsic Value
Price
R
What is Intrinsic Value?

See Also

What is Respiri Ltd's Capital Expenditures?
Capital Expenditures
0 AUD

Based on the financial report for Jun 30, 2024, Respiri Ltd's Capital Expenditures amounts to 0 AUD.

Back to Top
ALPHA SPREAD
Follow us
Join more than 202,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.